Tasquinimod is under clinical development by Active Biotech and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData, Phase II drugs for Post-Polycythemia Vera Myelofibrosis (PPV-MF) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tasquinimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tasquinimod overview
Tasquinimod (ABR-215050, TASQ) is under development for the treatment of relapsed and refractory multiple myeloma and primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), or post-essential thrombocytosis myelofibrosis (Post-ET MF). The drug candidate is administered orally. It acts by targeting protein S100A9. The drug candidate was under development for the treatment of advanced or metastatic hepatocellular carcinoma, metastatic castrate-resistant prostate cancer, epithelial ovarian cancer, fallopian tube or primary peritoneal cavity cancer, metastatic renal cell carcinoma and adenocarcinoma of gastroesophageal junction.
Active Biotech overview
Active Biotech is a biotechnology company that focuses on the development of therapeutics in the field of cancer, inflammatory eye disorders and neurodegenerative diseases. The company’s pipeline products include naptumomab for the treatment of solid tumors and lung cancer; tasquinimod for multiple myeloma; and laquinimod for the Uveitis. The portfolio comprises of antibody-based immunotherapy and small, orally active immunomodulatory molecules. It has partnerships with NeoTX Therapeutics Ltd and with the Perelman School of Medicine, University of Pennsylvania. The company’s products have patents and patent applications in markets of the US, Japan, and Europe. Active Biotech is headquartered in Lund, Sweden.
For a complete picture of Tasquinimod’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
